Sundise Successfully held the Fuzheng Huayu U.S. Phase ⅡClinical Trial Investigator Meeting in San Diego
During 2012 DDW (Digestive Disease Week), Shanghai Sundise Traditional Chinese Medicine Co., Ltd. (Sundise) held a Fuzheng Huayu (FZHY) U.S. Phase Ⅱ clinical trial investigator meeting on May 20th in Hilton Hotel San Diego, U.S.
This meeting was hosted by Mr. Jipu Wen, the U.S. business consultant of Sundise. The attendees include: the principle investigators from the clinical sites of FZHY U.S. clinical trial, the central pathologist of this study, our cooperator for the FZHY animal study Dr. Aleem Siddiqui from UCSD, and FZHY related medical experts from China.
The general manager of Sundise, Mr. Huashi Bian, made the opening remark for the meeting. After two years efforts of eight clinical sites, FZHY U.S. clinical trial is already more than half way through. Mr. Huashi Bian expressed sincere appreciation to all investigators on behalf of Sundise. Then our principle investigator Dr. Hassanein summarized the study status of FZHY U.S. clinical trial, and explained the evaluation method and procedure of liver biopsy slides assessment which is the effectiveness evaluation index of this clinical trial. This initiated the results evaluation system of FZHY U.S. Phase Ⅱ clinical trial against hepatic fibrosis in chronic hepatitis C patients on real significance.